Plerixafor hydrochloride: A novel agent for the mobilization of peripheral blood stem cells

Drugs of Today

Volumn 45, Issue 7, 2009, Pages 497-505

  Cashen, Amanda F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CD34 SELECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DONOR; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; REVIEW; SIBLING; STEM CELL MOBILIZATION;

ANIMALS; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

EID: 71249160513     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.7.1395292     Document Type: Review

References (40)

1. Siena, S., Schiavo, R., Pedrazzoli, P., Carlo-Stella, C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000, 18(6): 1360-1377 (Pubitemid 30159857)
2. Lane, T., Law, P., Maruyama, M. et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995, 85(1): 275-282
3. Peters, W., Rosner, G., Ross, M. et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993, 81(7): 1709-1719
4. Pusic, I., Jiang, S.Y., Landua, S. et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14(9): 1045-1056
5. Shpall, E.J., Wheeler, C.A., Turner, S.A. et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999, 93(8): 2491-2501
6. Gajewski, J.L., Rondon, G., Donato, M.L. et al. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 2002, 8(10): 550-556
7. Steidl, U., Fenk, R., Kondalkci, M. et al. Transplantation of peripheral blood stem cells mobilized by single dose application of pegylated G-CSF in patients with multiple myeloma. Blood [45th Annu Meet Am Soc Hematol (Dec 6-9, San Diego) 2003] 2003, 102(11): Abst 3554.
8. Fricker, S.P., Anastassov, V., Cox, J. et al. Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006, 72(5): 588-596
9. Gerlach, L.O., Skerlj, R.T., Bridger, G.J., Schwartz, T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001, 276(17): 14153-14160 (Pubitemid 37391801)
10. Peled, A., Petit, I., Kollet, O. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283(5403): 845-848
11. Petit, I., Szyper-Kravitz, M., Nagler, A. et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3(7): 687-94.
12. Levesque, J.-P., Hendy, J., Takamatsu, Y., Simmons, P.J., Bendall, L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111(2): 187-196
13. Lapidot, T., Petit, I. Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002, 30(9): 973-981 (Pubitemid 35286613)
14. Semerad, C.L., Christopher, M.J., Liu, F. et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005, 106(9): 3020-3027
15. Lack, N.A., Green, B., Dale, D.C. et al. A pharmacokinetic- pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 2005, 77(5): 427-436
16. MacFarland, R., Ewesuedo, R.B., Badel, K., Calandra, G. Pharmacokinetics of plerixafor (AMD3100) in volunteers with renal impairment. Blood [49th Annu Meet Am Soc Hematol (Dec 8-9, Atlanta) 2007] 2007, 110(1): Abst 2878.
17. Stewart, D.A., Smith, C., MacFarland, R., Calandra, G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009, 15(1): 39-46.
18. Cashen, A., Lopez, S., Gao, F. et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14(11): 1253-1261
19. Hendrix, C., Flexner, C., MacFarland, R. et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000, 44(6): 1667-1673
20. Hendrix, C.W., Collier, A.C., Lederman, M.M. et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004, 37(2): 1253-1262
21. Liles, W.C., Broxmeyer, H.E., Rodger, E. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102(8): 2728-2730
22. Liles, W.C., Rodger, E., Broxmeyer, H.E. et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45(3): 295-300.
23. Devine, S.M., Flomenberg, N., Vesole, D.H. et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004, 22(6): 1095-1102
24. Flomenberg, N., Devine, S.M., DiPersio, J.F. et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106(5): 1867-1874 (Pubitemid 41208607)
25. Gazitt, Y., Freytes, C.O., Akay, C., Badel, K., Calandra, G. Improved mobilization of peripheral blood CD34+ Cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Devel 2007, 16(4): 657-666 (Pubitemid 47378738)
26. Stiff, P., Micallef, I., McCarthy, P. et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009, 15(2): 249-256
27. Flomenberg, N., Comenzo, R., Badel, K., Calandra, G. Single agent AMD3100 mobilization of peripheral blood progenitor cells for autologous transplantation in patients with multiple myeloma (MM). Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 3381.
28. Dugan, M.J., Maziarz, R.T., Bensinger, W.I. et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization Bone Marrow Transplant 2009, doi:10.1038/bmt.2009.119.
29. Devine, S.M., Vij, R., Rettig, M. et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112(4): 990-998
30. Broxmeyer, H.E., Orschell, C.M., Clapp, D.W. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201(8): 1307-1318 (Pubitemid 40629073)
31. Hess, D.A., Bonde, J., Craft, T.C. et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007, 13(4): 398-411. (Pubitemid 46421895)
32. Larochelle, A., Krause, A., Metzger, M. et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006, 107(9): 3772-3778
33. Fruehauf, S., Seeger, T., Maier, P. et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006, 34(8): 1052-1059 (Pubitemid 44080394)
34. Burroughs, L., Mielcarek, M., Little, M.-T. et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005, 106(12): 4002-4008 (Pubitemid 41739045)
35. DiPersio, J.F., Micallef, I., Stiff, P.J. et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 601.
36. DiPersio, J.F., Stadtmauer, E.A., Nademanee, A. et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113(23): 5720-5726
37. Calandra, G., McCarty, J., McGuirk, J. et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplantation 2007, 41(4): 331-338
38. Micallef, I., Stiff, P.J., DiPersio, J.F. et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the phase III (3101-NHL) study. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 602.
39. Nervi, B., Ramirez, P., Rettig, M.P. et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113(24): 6206-6214
40. Uy, G.L., Rettig, M.P., McFarland, K.M. et al. Mobilization and chemosensitization of AML with the CXCR4 antagonist plerixafor (AMD3100): A phase I/II study of AMD3100+MEC in patients with relapsed or refractory disease. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1944.